XML 242 R185.htm IDEA: XBRL DOCUMENT v3.25.0.1
Provisions, income tax liabilities and other liabilities - Current Provisions and Other Current Liabilities (Details) - EUR (€)
€ in Millions
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2020
Dec. 31, 2021
Provisions And Other Current And Non-Current Liabilities [Line Items]          
Taxes payable, other than corporate income taxes € 437 € 395 € 420    
Employee-related liabilities 1,929 2,106 2,158    
Restructuring provisions (see Note D.19.2.) 653 578 472    
Interest rate derivatives (see Note D.20.) 7 1 0    
Currency derivatives (see Note D.20.) 330 126 94    
Equity derivatives (see Note D.20.) 0 0 0    
Amounts payable for acquisitions of non-current assets 878 945 714    
Customer contract liabilities [1] 0 0 269    
Other current liabilities [2],[3] 10,007 9,590 7,894    
Total 14,241 13,741 12,021    
Other revenues 3,205 3,801 [4],[5] 2,910 [4],[5]    
Contract liabilities   € 269      
US legal restructuring          
Provisions And Other Current And Non-Current Liabilities [Line Items]          
Percentage of capital losses used       33.33%  
Collaboration agreement with GSK          
Provisions And Other Current And Non-Current Liabilities [Line Items]          
Customer contract liabilities     € 269   € 319
Direct royalty agreement with SOBI on sales of BeyfortusTM in the United States          
Provisions And Other Current And Non-Current Liabilities [Line Items]          
Other current liabilities 290        
Royalties, payable € 273        
[1] (a)See Note A.5., “Agreements relating to the recombinant COVID-19 vaccine candidate developed by Sanofi in collaboration with GSK”. The year-on-year
change in this item between 2023 and 2022 includes revenue of €269 million recognized in profit or loss during 2023 (previously included in “Customer
contract liabilities” as of December 31, 2022).
[2] (c)As of December 31, 2024 includes €273 million (nominal value: €290 million) for the current liability relating to royalties payable to Sobi on net sales of Beyfortus (nirsevimab) in the United States (see Note C.2.)
[3] (b)“Other current liabilities” mainly comprises provisions and liabilities for customer rebates and returns; provisions for discounts and rebates granted to
healthcare authorities and governmental programs (see Note D.23.); and the liability payable at each reporting date under the Monoclonal Antibody
Alliance with Regeneron.
[4] Figures for comparative periods (2023 and 2022) have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation
[5] (a)Figures for comparative periods (2023 and 2022) have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued
operation.